GSA Capital Partners LLP Sells 10,075 Shares of Avantor, Inc. (NYSE:AVTR)

GSA Capital Partners LLP cut its stake in Avantor, Inc. (NYSE:AVTR) by 40.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,084 shares of the company’s stock after selling 10,075 shares during the period. GSA Capital Partners LLP’s holdings in Avantor were worth $390,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in AVTR. Versant Capital Management Inc grew its position in Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after purchasing an additional 1,102 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares in the last quarter. UMB Bank n.a. acquired a new stake in shares of Avantor in the third quarter valued at about $49,000. Nisa Investment Advisors LLC grew its stake in Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after purchasing an additional 835 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AVTR. Barclays cut their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Stifel Nicolaus boosted their price objective on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Avantor in a report on Thursday, September 26th. Robert W. Baird reduced their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, UBS Group dropped their price objective on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.57.

Avantor Trading Up 1.1 %

Shares of Avantor stock opened at $20.36 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The stock has a market cap of $13.86 billion, a PE ratio of 44.26, a PEG ratio of 2.39 and a beta of 1.35. Avantor, Inc. has a 52-week low of $19.59 and a 52-week high of $28.00. The firm has a 50-day moving average of $24.01 and a 200-day moving average of $23.89.

Insider Activity

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 10.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by company insiders.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.